Open Actively Recruiting

Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing

About

Brief Summary

This Master Protocol for Avelumab Continuation Sub-Studies is to provide continued treatment access, safety follow-up, and when applicable, overall survival follow-up for eligible participants who continue to derive a benefit from study intervention in the Pfizer-sponsored Avelumab parent studies.

Primary Purpose
Treatment
Study Type
Interventional
Phase
Phase 3

Eligibility

Gender
All
Healthy Volunteers
No
Minimum Age
18 Years
Maximum Age
N/A

Inclusion Criteria:

  • Any participant who is receiving study treatment and deriving significant clinical benefit or is in the safety and/or survival follow-up period in a Pfizer-sponsored Avelumab Parent Study.
  • Participants must agree to follow the reproductive criteria.
  • Participants must be willing and able to comply with all scheduled visits, treatment plan, and other study procedures.

Exclusion Criteria:

  • Female participants who are pregnant or breastfeeding.
  • Any medical reason that, in the opinion of the Investigator or Sponsor, precludes the participant from inclusion in the study.
Share:
Study Stats
Protocol No.
22-000710
Category
Adolescent & Young Adults (AYA)
Lung Cancer
Melanoma (Skin Cancer)
Contact
Elizabeth Seja
Location
  • UCLA Westwood
For Providers
NCT No.
NCT05059522
For detailed technical eligibility, visit ClinicalTrials.gov.